# A review of the pharmacological mechanism of corosolic acid

**Authors:** Xiaoyin Xu, Zhenduo Zhao, Jiaqi Zhang, Liang Shi, Wenhui Gao, Xi Yang, Xiaoting Zhang, Long Liu, Yanfeng Xu

PMC · DOI: 10.3389/fphar.2026.1723882 · Frontiers in Pharmacology · 2026-03-18

## TL;DR

This review examines the preclinical evidence and mechanisms of corosolic acid, a plant compound with potential health benefits, and highlights the need for more clinical research.

## Contribution

The paper provides a critical synthesis of corosolic acid's pharmacological mechanisms and identifies key gaps for future research.

## Key findings

- Corosolic acid shows promise in metabolic regulation and cancer therapy through multiple pathways.
- Current evidence lacks clinical validation despite strong preclinical results.
- Mechanistic insights remain inconsistent or superficial in several areas.

## Abstract

Corosolic Acid (CA), a pentacyclic triterpenoid found in plants like Lagerstroemia speciosa, exhibits a wide array of preclinical pharmacological activities, including hypoglycemic, anti-cancer, anti-inflammatory, antioxidant, and cardiovascular protective effects. Often dubbed “plant insulin,” its therapeutic potential has garnered significant interest. However, despite numerous in vitro and animal studies elucidating potential mechanisms involving pathways like AMPK, NF-κB, YAP, and various kinases, a critical gap exists between this promising preclinical data and robust clinical validation. This review critically evaluates the existing evidence for CA’s major pharmacological actions, focusing on the strength and limitations of current mechanistic understandings, identifying key inconsistencies and controversies in the literature (searched via PubMed, Scopus, Cochrane, Web of Science, etc.). We particularly scrutinize the evidence supporting its roles in metabolic regulation and cancer therapy, highlighting areas where mechanistic insights remain superficial or conflicting. By synthesizing these findings, we aim to identify critical knowledge gaps and propose a structured roadmap with specific, hypothesis-driven future research directions required to rigorously assess CA’s translational potential and pave the way for potential clinical applications.

## Linked entities

- **Proteins:** PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1), NFKB1 (nuclear factor kappa B subunit 1), YAP1 (Yes1 associated transcriptional regulator)
- **Chemicals:** Corosolic Acid (PubChem CID 6918774)

## Full-text entities

- **Diseases:** inflammatory (MESH:D007249), cancer (MESH:D009369)
- **Chemicals:** CA (MESH:C113861), pentacyclic triterpenoid (MESH:D053978)
- **Species:** Lagerstroemia speciosa (giant crepe-myrtle, species) [taxon 122810]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13038982/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13038982/full.md

## References

162 references — full list in the complete paper: https://tomesphere.com/paper/PMC13038982/full.md

---
Source: https://tomesphere.com/paper/PMC13038982